Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. (Q49041541)

18 February 2018

title

Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. (English)

1 reference

18 February 2018

author name string

B Brochet

1

1 reference

18 February 2018

M S A Deloire

2

1 reference

18 February 2018

M Bonnet

3

1 reference

18 February 2018

E Salort-Campana

4

1 reference

18 February 2018

J C Ouallet

5

1 reference

18 February 2018

K G Petry

6

1 reference

18 February 2018

V Dousset

7

1 reference

18 February 2018

publication date

24 July 2008

1 reference

18 February 2018

Multiple Sclerosis Journal

published in

1 reference

18 February 2018

volume

14

1 reference

18 February 2018

issue

9

1 reference

18 February 2018

page(s)

1242-1249

1 reference

18 February 2018

Cognitive impairment in multiple sclerosis.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Structural and functional surrogates of cognitive impairment at the very early stage of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive impairment in three subtypes of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Distinct Neurocognitive Profiles in Multiple Sclerosis Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive dysfunction in multiple sclerosis: a review of recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive disorders in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Selective decline in information processing in subgroups of multiple sclerosis: an 8-year longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

MRI markers of destructive pathology in multiple sclerosis-related cognitive dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Memory performance in multiple sclerosis patients correlates with central brain atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

The unique impact of changes in normal appearing brain tissue on cognitive dysfunction in secondary progressive multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Paced auditory serial-addition task: a measure of recovery from concussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

A comprehensive review of the Paced Auditory Serial Addition Test (PASAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Paced serial addition: modality-specific and arithmetic-specific factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

How to detect cognitive dysfunction at early stages of multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

International consensus statement on the use of disease-modifying agents in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Normative data for determining significance of test-retest differences on eight common neuropsychological instruments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Verbal fluency deficits in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

A longitudinal study of cognition in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458508094398

21 January 2018

Identifiers

DOI

10.1177/1352458508094398

1 reference

18 February 2018

1 reference

18 February 2018